Teva pharmaceutical industries ltd (TEVA)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09Mar'09Dec'08Sep'08Jun'08Mar'08
Net revenues

4,357

4,137

4,264

4,337

4,149

3,976

4,529

4,701

5,065

4,866

5,617

5,720

5,650

6,492

5,563

5,038

4,810

4,881

4,823

4,966

4,982

5,168

5,058

5,045

5,001

5,430

5,059

4,924

4,901

5,249

4,972

4,994

5,102

5,676

4,344

4,212

4,080

4,418

4,250

3,800

3,653

3,802

3,550

3,400

3,147

2,848

2,842

2,823

2,572

Cost of sales

2,294

2,180

2,435

2,443

2,293

2,005

2,552

2,668

2,750

2,594

2,967

2,865

2,811

3,308

2,762

2,161

2,019

2,034

2,052

2,064

2,146

2,279

2,249

2,384

2,304

2,536

2,429

2,331

2,311

2,464

2,371

2,337

2,493

2,795

2,098

2,012

1,892

1,954

1,783

1,679

1,640

1,703

1,622

1,631

1,576

1,249

1,350

1,318

1,200

Gross profit

2,063

1,958

1,830

1,893

1,856

1,971

1,977

2,033

2,315

2,271

2,650

2,855

2,839

3,184

2,801

2,877

2,791

2,847

2,771

2,902

2,836

2,889

2,809

2,661

2,697

2,894

2,630

2,593

2,590

2,785

2,601

2,657

2,609

2,881

2,246

2,200

2,188

2,464

2,467

2,121

2,013

2,099

1,928

1,769

1,571

1,599

1,492

1,505

1,372

Research and development expenses

221

233

240

276

261

295

311

290

317

346

531

469

432

650

663

375

389

446

361

386

332

379

412

344

353

411

348

339

329

442

324

298

292

371

242

243

239

288

239

217

207

242

195

169

219

215

194

198

179

Selling and marketing expenses

613

705

595

666

648

797

699

682

738

650

843

944

958

852

940

952

839

916

780

860

922

1,006

950

921

984

1,132

971

982

995

1,056

914

981

928

1,036

806

804

832

821

751

644

752

752

671

649

604

498

492

500

352

General and administrative expenses

304

319

285

296

292

344

309

316

329

350

372

363

366

465

310

311

304

412

316

325

307

320

293

302

302

316

297

319

307

318

292

316

312

315

112

284

221

258

236

189

182

218

212

197

196

182

156

169

162

Intangible assets impairments

649

432

177

561

469

745

519

521

206

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Goodwill impairment

-

-

-

-

-

2,727

0

120

180

-

-

6,100

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets impairments, restructuring and other items

121

161

160

101

1

153

139

194

501

627

550

419

240

409

-410

712

119

208

384

285

299

286

164

143

57

460

166

104

58

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Legal settlements and loss contingencies

-25

7

468

646

57

31

19

20

-1,278

176

-20

324

20

225

533

166

-25

100

-80

384

227

-44

-122

26

29

15

47

1,435

27

-620

1,131

55

149

721

51

-272

-29

488

-53

9

-34

-475

-97

-52

-14

-124

0

0

0

Other income

13

47

14

9

6

-43

35

96

203

1,099

4

24

72

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of research and development in process

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

5

4

-

0

0

-

992

28

0

382

Operating (loss) income

191

148

-81

-644

134

-3,164

16

-14

1,525

-13,017

378

-5,740

895

-137

765

361

1,165

931

1,010

662

749

942

1,112

925

972

560

801

-586

874

330

-60

1,007

928

610

1,035

597

867

774

1,188

1,075

834

412

753

702

538

-412

622

638

297

Financial expenses, net

-224

-187

-211

-206

-218

-223

-229

-236

-271

-191

-259

-238

-207

-777

-150

-105

-298

-70

-697

-41

-192

-70

-84

-78

-81

-59

-76

-89

-175

-146

-73

-97

-70

-68

-67

20

-38

-47

-3

-148

-27

-26

-52

-61

-63

-302

57

-34

-66

Income (loss) before income taxes

-33

-39

-292

-850

-84

-3,387

-213

-250

1,254

-13,208

119

-5,978

688

-914

615

256

867

861

313

621

557

872

1,028

847

891

501

725

-675

699

184

-133

910

858

542

968

617

829

727

1,185

927

807

386

701

641

475

-714

679

604

231

Income taxes (benefit)

-59

-119

11

-179

9

-139

-26

-76

46

-1,471

-494

-22

54

57

207

29

228

249

193

88

104

186

160

102

143

114

12

-222

53

-110

-57

39

-9

18

33

27

49

-53

133

118

85

-6

49

98

25

-23

47

68

92

Income before minority interest earnings and equity investments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,052

-809

-722

-

-652

-543

450

-1,923

632

536

139

Share in (profits) losses of associated companies, net

-1

-5

-4

0

-4

5

-10

8

-74

7

-3

-14

7

-3

2

15

-6

-114

-4

6

-9

8

-5

0

-8

-10

-7

-3

-20

-14

-8

-12

-12

-19

-17

-10

-15

-7

0

-9

-8

-12

-2

-20

1

-1

0

-1

1

Net income (loss)

25

75

-307

-671

-97

-3,243

-197

-166

1,134

-11,730

610

-5,970

641

-974

410

242

633

498

116

539

444

694

863

745

740

377

706

-456

626

280

-84

859

855

505

918

580

765

773

1,052

800

714

380

650

523

451

-692

632

535

140

Net income (loss) attributable to non-controlling interests

-44

-35

7

18

8

-357

11

10

14

-195

15

0

-4

-1

-2

-12

-3

-2

13

0

-2

7

-13

-3

-4

-3

-5

-4

-4

-40

-5

-4

-4

-1

2

4

4

2

2

3

1

1

1

2

0

2

1

2

1

Net income (loss) attributable to Teva

69

109

-314

-689

-105

-2,886

-208

-176

1,120

-11,535

595

-5,970

645

-973

412

254

636

500

103

539

446

687

876

748

744

380

711

-452

630

320

-79

863

859

506

916

576

761

771

1,050

797

713

379

649

521

451

-694

631

533

139

Accrued dividends on preferred shares

-

-

-

-

-

54

65

65

65

65

65

65

65

65

64

66

66

15

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) attributable to ordinary shareholders

69

109

-314

-689

-105

-2,940

-273

-241

1,055

-11,600

530

-6,035

580

-1,038

348

188

570

485

103

539

446

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Earnings (loss) per share attributable to ordinary shareholders:
Basic

0.06

0.11

-0.29

-0.63

-0.10

-2.88

-0.27

-0.24

1.04

-11.41

0.52

-5.94

0.57

-1.11

0.35

0.21

0.62

0.56

0.12

0.64

0.52

0.80

1.02

0.88

0.88

0.44

0.84

-0.53

0.74

0.37

-0.09

0.99

0.98

0.57

1.03

0.65

0.85

0.86

1.17

0.89

0.80

0.42

0.73

0.61

0.53

-0.89

0.81

0.68

0.18

Diluted

0.06

0.11

-0.29

-0.63

-0.10

-2.87

-0.27

-0.24

1.03

-11.41

0.52

-5.94

0.57

-1.10

0.35

0.20

0.62

0.55

0.12

0.63

0.52

0.80

1.02

0.87

0.87

0.44

0.84

-0.53

0.74

0.38

-0.09

0.99

0.97

0.58

1.03

0.64

0.84

0.85

1.15

0.88

0.79

0.42

0.72

0.58

0.51

-0.85

0.77

0.65

0.18

Weighted average number of shares (in millions):
Basic

1,093

1,090

1,092

1,092

1,090

1,031

1,018

1,018

1,017

1,014

1,017

1,017

1,016

-2,805

979

914

913

869

851

849

851

855

855

852

850

847

845

849

855

868

869

871

880

883

888

892

897

898

899

895

892

887

884

860

857

784

782

778

776

Diluted

1,096

1,090

1,092

1,092

1,090

1,028

1,018

1,018

1,020

1,013

1,017

1,017

1,017

-2,823

984

920

920

876

862

859

859

862

861

857

852

849

846

849

856

868

869

873

882

884

890

896

902

921

921

921

921

880

915

895

894

790

837

836

817